Global Ganirelix Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Ganirelix Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Ganirelix acetate (or diacetate), is an injectable competitive gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in assisted reproduction to control ovulation. The drug works by blocking the action of GnRH upon the pituitary, thus rapidly suppressing the production and action of LH and FSH. Ganirelix is used in fertility treatment to prevent premature ovulation that could result in the harvesting of eggs that are too immature to be used in procedures such as in vitro fertilization
Ganirelix report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Ganirelix market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Polycystic Ovaries Syndrome and Ovarian Stimulation are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Ganirelix industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Ganirelix key manufacturers include Organon, Sun Pharm, Merck Sharp and Dohme (MSD), Ferring Pharmaceuticals, Ambinter, BLD Pharm and Chemenu, etc. Organon, Sun Pharm, Merck Sharp and Dohme (MSD) are top 3 players and held % sales share in total in 2022.
Ganirelix can be divided into Patent and Generic, etc. Patent is the mainstream product in the market, accounting for % sales share globally in 2022.
Ganirelix is widely used in various fields, such as Polycystic Ovaries Syndrome, Ovarian Stimulation, Orthostatic Intolerance and Controlled Ovarian Stimulation, etc. Polycystic Ovaries Syndrome provides greatest supports to the Ganirelix industry development. In 2022, global % sales of Ganirelix went into Polycystic Ovaries Syndrome filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Ganirelix market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Organon
Sun Pharm
Merck Sharp and Dohme (MSD)
Ferring Pharmaceuticals
Ambinter
BLD Pharm
Chemenu
Segment by Type
Patent
Generic
Polycystic Ovaries Syndrome
Ovarian Stimulation
Orthostatic Intolerance
Controlled Ovarian Stimulation
Infertility
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Ganirelix market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Ganirelix, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Ganirelix industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Ganirelix in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Ganirelix introduction, etc. Ganirelix Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Ganirelix market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Ganirelix report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Ganirelix market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Polycystic Ovaries Syndrome and Ovarian Stimulation are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Ganirelix industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Ganirelix key manufacturers include Organon, Sun Pharm, Merck Sharp and Dohme (MSD), Ferring Pharmaceuticals, Ambinter, BLD Pharm and Chemenu, etc. Organon, Sun Pharm, Merck Sharp and Dohme (MSD) are top 3 players and held % sales share in total in 2022.
Ganirelix can be divided into Patent and Generic, etc. Patent is the mainstream product in the market, accounting for % sales share globally in 2022.
Ganirelix is widely used in various fields, such as Polycystic Ovaries Syndrome, Ovarian Stimulation, Orthostatic Intolerance and Controlled Ovarian Stimulation, etc. Polycystic Ovaries Syndrome provides greatest supports to the Ganirelix industry development. In 2022, global % sales of Ganirelix went into Polycystic Ovaries Syndrome filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Ganirelix market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Organon
Sun Pharm
Merck Sharp and Dohme (MSD)
Ferring Pharmaceuticals
Ambinter
BLD Pharm
Chemenu
Segment by Type
Patent
Generic
Segment by Application
Polycystic Ovaries Syndrome
Ovarian Stimulation
Orthostatic Intolerance
Controlled Ovarian Stimulation
Infertility
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Ganirelix market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Ganirelix, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Ganirelix industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Ganirelix in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Ganirelix introduction, etc. Ganirelix Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Ganirelix market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices